Entering text into the input field will update the search result below

CytomX downgraded at several Street firms following breast cancer therapy results

Jul. 07, 2022 8:43 AM ETCytomX Therapeutics, Inc. (CTMX)ABBVBy: Jonathan Block, SA News Editor

Wall Street sign, New York City, USA

mbbirdy/E+ via Getty Images

  • Several Street firms have downgraded CytomX Therapeutics (NASDAQ:CTMX) after the company released disappointing phase 2 results on praluzatamab ravtansine for breast cancer Wednesday.
  • Shares are down 26% in Thursday premarket trading.
  • CytomX (CTMX) said it will

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

About CTMX

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CytomX Therapeutics, Inc.
Atossa Therapeutics, Inc.
Genenta Science S.p.A.
Werewolf Therapeutics, Inc.
Generation Bio Co.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.